Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
